Xuening H. Duan
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Low Breast Cancer With Cancer-Related Microangiopathic Hemolytic Anemia: A Case Report.
Journal: Cancer innovation
Published: July 06, 2025
Breast Cancer Awareness and Association with Frequency of Screening Among Women - China, 2020.
Journal: China CDC weekly
Published: February 28, 2023
A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression.
Journal: Chinese medical journal
Published: January 26, 2023
Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).
Journal: Chinese medical journal
Published: December 19, 2022
Correlation between Androgen Receptor Expression in Luminal B (HER-2 Negative) Breast Cancer and Disease Outcomes.
Journal: Journal of personalized medicine
Published: October 09, 2022
Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy.
Journal: Journal of personalized medicine
Published: December 26, 2021
Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021).
Journal: Chinese medical journal
Published: November 13, 2021
Single-Nucleotide Polymorphisms in LEP and LEPR Associated With Breast Cancer Risk: Results From a Multicenter Case-Control Study in Chinese Females.
Journal: Frontiers in oncology
Published: November 05, 2021
Last Updated: 09/26/2026